MARKET

IDYA

IDYA

Ideaya Biosciences
NASDAQ
36.74
+0.45
+1.24%
After Hours: 36.00 -0.74 -2.01% 18:30 06/26 EDT
OPEN
36.60
PREV CLOSE
36.29
HIGH
37.02
LOW
36.02
VOLUME
3.68M
TURNOVER
--
52 WEEK HIGH
39.28
52 WEEK LOW
20.50
MARKET CAP
3.43B
P/E (TTM)
-23.0013
1D
5D
1M
3M
1Y
5Y
1D
IDEAYA Biosciences grants inducement stock options for 98,000 shares at $36.29 each
PUBT · 13h ago
IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 13h ago
Press Release: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 13h ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 13h ago
IDEAYA Biosciences (IDYA) First Patient Enrollment Puts Valuation Back In Focus
Simply Wall St · 1d ago
IDEAYA Biosciences Shareholders Back Leadership, Governance Changes
TipRanks · 3d ago
IDEAYA Biosciences shareholders ratified PwC as auditor for 2026
PUBT · 3d ago
IDEAYA Biosciences (IDYA) Is Up 13.2% After New MTAP Trial And Roche Collaboration - Has The Bull Case Changed?
Simply Wall St · 4d ago
More
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.

Webull offers Ideaya Biosciences Inc stock information, including NASDAQ: IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IDYA stock methods without spending real money on the virtual paper trading platform.